Sarepta Therapeutics reported $385.98M in Trade Debtors for its fiscal quarter ending in September of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 178.32M 11.98M Sep/2026
Agios Pharmaceuticals USD 24.22M 8.08M Jun/2026
Alnylam Pharmaceuticals USD 1.08B 172.17M Sep/2026
Amgen USD 10.35B 126M Sep/2026
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
Biogen USD 2.38B 15.8M Sep/2026
BioMarin Pharmaceutical USD 1.08B 15.31M Sep/2026
Capricor Therapeutics USD 59K 0 Dec/2025
Daiichi Sankyo JPY 700.97B 24.05B Sep/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
Incyte USD 1.24B 111.82M Sep/2026
Insmed USD 259.27M 43.94M Sep/2026
Ionis Pharmaceuticals USD 88M 29.15M Sep/2026
Moderna USD 1.37B 1.35B Sep/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Neurocrine Biosciences USD 957.3M 70.3M Sep/2026
Novavax USD 106.45M 72.27M Dec/2025
Pfizer USD 17.57B 1.38B Sep/2026
PTC Therapeutics USD 239.04M 19.12M Jun/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 326M 166M Sep/2026
Sarepta Therapeutics USD 385.98M 7.82M Sep/2026
Tectonic Therapeutic USD 0 270K Dec/2023
Ultragenyx Pharmaceutical USD 200M 140M Jun/2026
Vertex Pharmaceuticals USD 2.31B 176.7M Sep/2026